Aequus Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Doug Janzen

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	11.8yrs
Participación del CEO	9.5%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Doug Janzen en comparación con los beneficios de Aequus Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-CA$3m
Jun 30 2024	n/a	n/a	-CA$3m
Mar 31 2024	n/a	n/a	-CA$3m
Dec 31 2023	n/a	n/a	-CA$3m
Sep 30 2023	n/a	n/a	-CA$3m
Jun 30 2023	n/a	n/a	-CA$3m
Mar 31 2023	n/a	n/a	-CA$3m
Dec 31 2022	CA$206k	CA$206k	-CA$3m
Sep 30 2022	n/a	n/a	-CA$3m
Jun 30 2022	n/a	n/a	-CA$2m
Mar 31 2022	n/a	n/a	-CA$2m
Dec 31 2021	CA$225k	CA$225k	-CA$2m
Sep 30 2021	n/a	n/a	-CA$2m
Jun 30 2021	n/a	n/a	-CA$2m
Mar 31 2021	n/a	n/a	-CA$1m
Dec 31 2020	CA$212k	CA$212k	-CA$1m
Sep 30 2020	n/a	n/a	-CA$2m
Jun 30 2020	n/a	n/a	-CA$2m
Mar 31 2020	n/a	n/a	-CA$3m
Dec 31 2019	CA$191k	CA$191k	-CA$3m
Sep 30 2019	n/a	n/a	-CA$3m
Jun 30 2019	n/a	n/a	-CA$3m
Mar 31 2019	n/a	n/a	-CA$3m
Dec 31 2018	CA$180k	CA$180k	-CA$3m
Sep 30 2018	n/a	n/a	-CA$3m
Jun 30 2018	n/a	n/a	-CA$3m
Mar 31 2018	n/a	n/a	-CA$4m
Dec 31 2017	CA$258k	CA$210k	-CA$4m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Doug es razonable en comparación con empresas de tamaño similar en el mercado German.

Compensación vs. Ingresos: La compensación de Doug ha sido consistente con los resultados de la empresa en el último año.

CEO

Doug Janzen (55 yo)

11.8yrs

Permanencia

Mr. Douglas Glen Janzen, also known as Doug, is Director of Elevate Farms Inc. from September 2022. Mr. Janzen has experience in banking investments and managing growth companies with a particular focus on...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Douglas Janzen	Chairman	11.8yrs	sin datos	9.46% € 43.1k
Marc Lustig	Independent Director	3.8yrs	CA$3.72k	5.21% € 23.8k
Christopher Clark	Director	9.9yrs	CA$3.72k	sin datos
Iqbal Ahmed	Chairman of Strategic Advisory Board	6yrs	sin datos	sin datos
Anne Stevens	Director	9.9yrs	CA$3.72k	sin datos
Rosa Braga-Mele	Member of Strategic Advisory Board	6yrs	sin datos	sin datos
Vikram Lekhi	Member of Strategic Advisory Board	6yrs	sin datos	sin datos
Ken Patterson	Member of Strategic Advisory Board	6yrs	sin datos	sin datos

6.0yrs

Permanencia media

51yo

Promedio de edad

Junta con experiencia: La junta directiva de AEQ se considera experimentada (6 años de antigüedad promedio).

Aequus Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Less than half of directors are independent

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)

Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022)

Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada

Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada

First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)

Aequus Pharmaceuticals Inc. Expects Health Canada Approval for Zimed® PF (Preservative Free)

Less than half of directors are independent

Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 2Q 2021)

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

Aequus Pharmaceuticals Inc. Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication

High number of new directors

Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020)

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.011 loss per share (vs CA$0.039 loss in FY 2019)

Aequus Pharmaceuticals Inc. Launches Evolve Eyedrops to Eye Care Professionals in Canada

Aequus Pharmaceuticals Inc. announced that it has received CAD 1 million in funding

Aequus Pharmaceuticals Inc. Appoints Marc Lustig as a Director

Aequus Pharmaceuticals Inc. announced that it expects to receive CAD 1 million in funding

Third quarter 2020 earnings released: CA$0.003 loss per share

Aequus Pharmaceuticals Inc. Announces Resignation of Anne Stevens as Chief Operating Officer

Aequus Pharmaceuticals Inc. Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada

Aequus Pharmaceuticals Inc. Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada with Sandoz Canada Inc

Aequus Announces Expansion of Medicom Partnership and Filing with Health Canada for Additional Evolve Dry Eye Product

First half earnings released

Aequus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 2.5 million.

Aequus Pharmaceuticals Inc.(TSXV:AQS) dropped from S&P/TSX Venture Composite Index

Análisis de compensación del CEO

CEO

Permanencia

Miembros de la Junta

Permanencia media

Promedio de edad